Brain-Computer interface aimed at boosting attention in kids with epilepsy – but study never started
NCT ID NCT06940089
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study planned to test whether a brain-computer interface (BCI) could help children with drug-resistant epilepsy improve their attention. Participants would have used brain electrodes already implanted for epilepsy surgery to train a decoder that gives real-time feedback when they focus. The trial was withdrawn before enrolling anyone, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- brain-computer interface (BCI) decoder with real-time visual feedback
- What this could lead to
- If it worked, this could point toward a non-drug therapy to help children with epilepsy improve their attention.
- What could go wrong
- The study was withdrawn before any participants were enrolled, so no results are available. It is unclear if the approach would be safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dell Children's Medical Center
Austin, Texas, 78723, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can community hospitals in zambia master severe disease care?
- Can mindfulness rewire the mind to lift depression in epilepsy?
- A break from seizure pills: could less medication mean better living?
- Can invisible electric fields quiet the Brain's seizure signals?
- Can a new drug tame severe childhood epilepsy?